The recommendations listed in this document are, whenever possible, evidence based.
Writing group members performed these relevant supplemental literature searches with key …

▪ Abstract Statins are potent inhibitors of cholesterol biosynthesis. In clinical trials, statins are
beneficial in the primary and secondary prevention of coronary heart disease. However, the …

Figure 2. Regulation of the Rho GTPase cycle. Rho protein cycle between an inactive GDP-
bound and an active GTP-bound state. Inhibition of the mevalonate synthesis by statins …

Chronic inflammation is a key feature of vascular disease states such as atherosclerosis.
Multiple clinical studies have shown that a class of medications termed statins lower …

Mevalonate pathway is an important metabolic pathway which plays a key role in multiple
cellular processes by synthesizing sterol isoprenoids, such as cholesterol, and non-sterol …

The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors or statins are potent
inhibitors of cholesterol biosynthesis. Several large clinical trials have demonstrated the …

Currently, five different statins (simvastatin, pravastatin, lovastatin, fluvastatin, and
atorvastatin) are approved for treatment of hypercholesterolemia in humans and two new …

The endothelium produces a number of vasodilator and vasoconstrictor substances that not
only regulate vasomotor tone, but also the recruitment and activity of inflammatory cells and …

The Japanese Circulation Society (JCS) published the “Guidelines for elective percutaneous
coronary intervention [PCI] in patients with stable coronary disease” in 2000. In 2006 …

Statins are 3-hydroxy-3-methyglutaryl coenzyme A (HMG-CoA) reductase inhibitors, which
are prescribed extensively for cholesterol lowering in the primary and secondary prevention …